Clinical trial readout dates for Adaptive Biotechnologies Corporation, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$3.6B
Cash & investments$400Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04
In progress, no date published
Phase 3Modakafusp alfa (TAK-573)
Relapsed/Refractory Multiple Myeloma
date not published
Trial Planned
Cash position
Adaptive Biotechnologies Corporation reported $400M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $3M for that quarter.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates